The landscape of dementia prognosis has evolved radically with the advent of subtle biomarkers, which includes amyloid PET scans, tau imaging, and blood-centered tests that could detect Alzheimer's pathology decades prior to indicators arise. While these technological developments depict remarkable progress in knowing neurodegenerative disorders, t